ArticlePulmonary therapy2026
Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics.
Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionClinical trials report no increased malignancy risk with benralizumab in severe asthma; however, trial populations are highly selective. To better define real-world safety, malignancy risk was compared among patients treated with benralizumab, other (non-benralizumab) biologics, or non-biologic therapies.
methodsData from adults with severe asthma accrued to the International Severe Asthma Registry (ISAR) and a United States severe asthma registry (CHRONICLE) between 1 November 2017, and 31 December 2023, were analyzed. Cohorts were defined by exposure to benralizumab, other asthma biologics, and non-exposure to biologic therapies. First new-onset malignancies were assessed. Incidence per 1000 person-years (PY) and adjusted incidence rate ratios (aIRR) were estimated with an inverse probability-weighted Poisson model, with propensity scores incorporating demographics, comorbidities, baseline asthma medication, systemic steroid use, and relevant medical history, with residual adjustment for age, sex, body mass index, region, and smoking.
resultsAmong 12,493 patients, 43,434.8 PY were accrued (benralizumab, 7749.1 PY; other biologics, 21,054.1 PY; non-biologics, 14,631.6 PY), with a median (range) follow-up of 3.3 (0-6.2) years across cohorts. Seventy-five patients reported new malignancies: benralizumab, 17 (0.7%); other biologics, 34 (0.6%); and non-biologics, 24 (0.5%). Weighted, fully adjusted incidence rates were 1.3 versus 1.1 per 1000 PY for benralizumab versus other biologics (aIRR 1.2, 95% CI 0.79-1.81) and 1.8 versus 1.7 per 1000 PY for benralizumab versus non-biologics (aIRR 1.1, 95% CI 0.70-1.59).
conclusionsThis large observational study with up to 6 years of follow-up found no increased malignancy risk with benralizumab versus other therapies in patients with severe asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.